Cargando…

Host proviral and antiviral factors for SARS-CoV-2

Throughout the viral life cycle, interplays between cellular host factors and virus determine the infectious capacity of the virus. The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a great threat to human life and health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Lu, Zhang, Leiliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Review Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435179/ https://www.ncbi.nlm.nih.gov/pubmed/34510331 http://dx.doi.org/10.1007/s11262-021-01869-2

Ejemplares similares

ACE2 partially dictates the host range and tropism of SARS-CoV-2
por: Gao, Shan, et al.
Publicado: (2020)

Aryl hydrocarbon receptor is a proviral host factor and a candidate pan-SARS-CoV-2 therapeutic target
por: Shi, Jiandong, et al.
Publicado: (2023)

Flavivirus–host interactions: an expanding network of proviral and antiviral factors
por: Schneider, William M, et al.
Publicado: (2022)

The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2
por: Aliyari, Saba R., et al.
Publicado: (2022)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection
por: Luan, Junwen, et al.
Publicado: (2020)

The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity
por: Gu, Wenjing, et al.
Publicado: (2022)

SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein
por: Walter, Marius, et al.
Publicado: (2022)

SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein
por: Walter, Marius, et al.
Publicado: (2022)

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

Host DDX Helicases as Possible SARS-CoV-2 Proviral Factors: A Structural Overview of Their Hijacking Through Multiple Viral Proteins
por: Squeglia, Flavia, et al.
Publicado: (2020)

Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2
por: Israeli, Ma’ayan, et al.
Publicado: (2022)

Role of host factors in SARS-CoV-2 entry
por: Evans, John P., et al.
Publicado: (2021)

G-Quadruplexes Are Present in Human Coronaviruses Including SARS-CoV-2
por: Cui, Haoran, et al.
Publicado: (2020)

A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2
por: Luan, Junwen, et al.
Publicado: (2020)

STAT3 roles in viral infection: antiviral or proviral?
por: Chang, Zhangmei, et al.
Publicado: (2018)

SARS‐CoV‐2–host proteome interactions for antiviral drug discovery
por: Liu, Xiaonan, et al.
Publicado: (2021)

Inhibition of endocytic recycling of ACE2 by SARS-CoV-2 S protein partially explains multiple COVID-19 related diseases caused by ACE2 reduction
por: Ren, Yongwen, et al.
Publicado: (2022)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Host antiviral factors hijack furin to block SARS-CoV-2, ebola virus, and HIV-1 glycoproteins cleavage
por: Yu, Changqing, et al.
Publicado: (2023)

Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors
por: Li, Daoqun, et al.
Publicado: (2021)

The importance of activated TMPRSS2 in the proviral role of small extracellular vesicles in SARS‐CoV‐2 infection
por: Tey, Sze Keong, et al.
Publicado: (2022)

Potential antiviral peptides against the nucleoprotein of SARS-CoV-2
por: Mahdi, Iktedar, et al.
Publicado: (2022)

Mechanisms of Antiviral Immune Evasion of SARS-CoV-2
por: Beyer, Daniel K., et al.
Publicado: (2022)

The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
por: Jans, David A., et al.
Publicado: (2021)

The Mutation Profile of SARS-CoV-2 Is Primarily Shaped by the Host Antiviral Defense
por: Azgari, Cem, et al.
Publicado: (2021)

SARS-CoV-2–host cell surface interactions and potential antiviral therapies
por: Butnariu, Aura-Bianca, et al.
Publicado: (2021)

Cytoplasmic tail determines the membrane trafficking and localization of SARS-CoV-2 spike protein
por: Li, Qinlin, et al.
Publicado: (2022)

Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection
por: Khezri, Mohammad Rafi, et al.
Publicado: (2021)

SARS-CoV-2 cell entry and targeted antiviral development
por: Chen, Zinuo, et al.
Publicado: (2021)

SARS-CoV-2 main protease cleaves MAGED2 to antagonize host antiviral defense
por: Ju, Xiaohui, et al.
Publicado: (2023)

Viral, host and environmental factors that favor anthropozoonotic spillover of coronaviruses: An opinionated review, focusing on SARS-CoV, MERS-CoV and SARS-CoV-2
por: da Silva, Priscilla Gomes, et al.
Publicado: (2021)

First-generation oral antivirals against SARS-CoV-2
por: Sendi, Parham, et al.
Publicado: (2022)

Proviral role of human respiratory epithelial cell‐derived small extracellular vesicles in SARS‐CoV‐2 infection
por: Berry, François, et al.
Publicado: (2022)

SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals
por: Gassen, Nils C., et al.
Publicado: (2021)

Key Components of Inflammasome and Pyroptosis Pathways Are Deficient in Canines and Felines, Possibly Affecting Their Response to SARS-CoV-2 Infection
por: Cui, Haoran, et al.
Publicado: (2021)

Host genomics of SARS-CoV-2 infection
por: Redin, Claire, et al.
Publicado: (2022)

Aminoglycosides and their potential as SARS-CoV-2 antivirals
por: Cimolai, Nevio
Publicado: (2021)

SARS-CoV-2 rebound with and without antivirals
por: Petrosillo, Nicola
Publicado: (2023)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cgdg36m12gacrv02jj0pubpv7q